A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma

Recruiting now · Phase 2

Conditions studied: Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma

In brief

To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG

Key facts

Study ID

NCT07589257

Run by

Guangzhou Virotech Pharmaceutical Co., Ltd.

People needed

10

Starts

2026-05-07

Expected to finish

2028-12-31

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study procedures.
• Male or female adults aged 18 to 75 years at the time of signing the ICF.
• Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI: tumor originating in the pons, occupying >50% of the pons volume, with diffuse brainstem enlargement.
• Karnofsky Performance Status (KPS) score ≥ 60.
• Expected survival time ≥ 3 months.

You may not qualify if…

• Individuals with extracranial metastases.
• Presence of spinal cord tumors or evidence of leptomeningeal disease dissemination.
• Active hemorrhage detected on cranial MRI scan prior to enrollment.
• Inability to undergo cranial MRI scanning (e.g., due to contraindications or incompatible implants).
• Prior receipt of oncolytic virus therapy or other gene therapy agents.

Where it is running

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.